ID: ALA4871912

Max Phase: Preclinical

Molecular Formula: C17H15F3N2O

Molecular Weight: 320.31

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O=C(Nc1ccc(C(F)(F)F)cc1)C1NCCc2ccccc21

Standard InChI:  InChI=1S/C17H15F3N2O/c18-17(19,20)12-5-7-13(8-6-12)22-16(23)15-14-4-2-1-3-11(14)9-10-21-15/h1-8,15,21H,9-10H2,(H,22,23)

Standard InChI Key:  SADUFJPTVYNQQI-UHFFFAOYSA-N

Associated Targets(Human)

NUGC-3 976 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

ACHN 49357 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

NCI-H23 49055 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HCT-15 51914 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-231 73002 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PC-3 62116 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 320.31Molecular Weight (Monoisotopic): 320.1136AlogP: 3.53#Rotatable Bonds: 2
Polar Surface Area: 41.13Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.14CX Basic pKa: 7.57CX LogP: 3.57CX LogD: 3.18
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.89Np Likeness Score: -0.84

References

1. Sim S, Lee S, Ko S, Phuong Bui B, Linh Nguyen P, Cho J, Lee K, Kang JS, Jung JK, Lee H..  (2021)  Design, synthesis, and biological evaluation of potent 1,2,3,4-tetrahydroisoquinoline derivatives as anticancer agents targeting NF-κB signaling pathway.,  46  [PMID:34500188] [10.1016/j.bmc.2021.116371]

Source